Cargando…

A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice

BACKGROUND: Rabies is a lethal zoonotic disease that kills approximately 60,000 people each year. Although inactivated rabies vaccines are available, multiple-dose regimensare recommended for pre-exposure prophylaxis or post-exposure prophylaxis,which cuts down the cost- and time-effectiveness, espe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Shimeng, Yang, Tianhan, Zhu, Cuisong, Feng, Meiqi, Zhang, Li, Zhang, Ziling, Wang, Xiang, Yu, Rui, Pan, Xinghao, Zhao, Chen, Xu, Jianqing, Zhang, Xiaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907168/ https://www.ncbi.nlm.nih.gov/pubmed/36761167 http://dx.doi.org/10.3389/fimmu.2022.1099991

Ejemplares similares

Corrigendum: A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice
por: Bai, Shimeng, et al.
Publicado: (2023)

An mRNA vaccine against rabies provides strong and durable protection in mice
por: Li, Miao, et al.
Publicado: (2023)

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques
por: Pardi, Norbert, et al.
Publicado: (2019)

Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB/c mice against acute toxoplasmosis
por: Zhang, Yizhuo, et al.
Publicado: (2023)

Zika virus protection by a single low dose nucleoside modified mRNA vaccination
por: Pardi, Norbert, et al.
Publicado: (2017)

Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice
por: Freyn, Alec W., et al.
Publicado: (2021)

A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice
por: Cao, Kangli, et al.
Publicado: (2022)

β-Glucan as Trained Immunity-Based Adjuvants for Rabies Vaccines in Dogs
por: Paris, Simon, et al.
Publicado: (2020)

Prompt Antiviral Action of Pulmonary CD8+ T(RM) Cells Is Mediated by Rapid IFN-γ Induction and Its Downstream ISGs in the Lung
por: Jiang, Lang, et al.
Publicado: (2022)

Case Report: Rabies Vaccine-Induced Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematosus
por: Cui, Yanming, et al.
Publicado: (2022)

Advances in mRNA Vaccines for Infectious Diseases
por: Zhang, Cuiling, et al.
Publicado: (2019)

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
por: Granados-Riveron, Javier T., et al.
Publicado: (2021)

Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy
por: Duan, Li-Juan, et al.
Publicado: (2022)

Neutralizing Antibody Response in Dogs and Cats Inoculated with Commercial Inactivated Rabies Vaccines
por: SHIRAISHI, Rikiya, et al.
Publicado: (2013)

Recombinant rabies virus expressing dog GM-CSF is an efficacious oral rabies vaccine for dogs
por: Zhou, Ming, et al.
Publicado: (2015)

Inactivated Rabies Virus Vectored MERS-Coronavirus Vaccine Induces Protective Immunity in Mice, Camels, and Alpacas
por: Chi, Hang, et al.
Publicado: (2022)

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses
por: Pardi, Norbert, et al.
Publicado: (2018)

Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine
por: Muramatsu, Hiromi, et al.
Publicado: (2022)

Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
por: Pardi, Norbert, et al.
Publicado: (2022)

Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
por: McMahon, Meagan, et al.
Publicado: (2022)

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy
por: Hu, Chaoying, et al.
Publicado: (2023)

mRNA vaccines for cancer immunotherapy
por: Vishweshwaraiah, Yashavantha L., et al.
Publicado: (2022)

Nucleoside-Modified mRNA Vaccines Protect IFNAR(–/–) Mice against Crimean-Congo Hemorrhagic Fever Virus Infection
por: Appelberg, Sofia, et al.
Publicado: (2022)

Comparing the pertussis antibody levels of healthy children immunized with four doses of DTap-IPV/Hib (Pentaxim) combination vaccine and DTaP vaccine in Quzhou, China
por: Yin, Zhiying, et al.
Publicado: (2023)

Construction and immunogenicity of an mRNA vaccine against chikungunya virus
por: Liu, Jingjing, et al.
Publicado: (2023)

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
por: Dominelli, Federica, et al.
Publicado: (2022)

Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines
por: Palatnik-de-Sousa, Clarisa Beatriz
Publicado: (2019)

Edible Rabies Vaccines
por: Loza-Rubio, Elizabeth, et al.
Publicado: (2014)

Influenza Viruses: Innate Immunity and mRNA Vaccines
por: Lee, SangJoon, et al.
Publicado: (2021)

Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development
por: Lin, Han, et al.
Publicado: (2022)

Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer
por: Zhang, Xin, et al.
Publicado: (2022)

Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases
por: Yang, Lu, et al.
Publicado: (2022)

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
por: Saunders, Kevin O., et al.
Publicado: (2021)

Rapid generation of a mouse model for evaluating on-target normal tissue toxicity of human CAR-T cells using replication-defective recombinant adenovirus
por: Liao, Qibin, et al.
Publicado: (2022)

Advancing mRNA technologies for therapies and vaccines: An African context
por: Kairuz, Dylan, et al.
Publicado: (2022)

SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
por: Ma, Qinhai, et al.
Publicado: (2023)

Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered
por: López-Cortés, Luis F., et al.
Publicado: (2023)

Gastric Subserous Vaccination With Helicobacter pylori Vaccine: An Attempt to Establish Tissue-Resident CD4+ Memory T Cells and Induce Prolonged Protection
por: Liu, Wei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1qsbc55c6b0mco8spj92mhfmp7